In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 4, 1998, Pages 275-277

  Alarcon T ^a   Domingo, D ^a   Sanchez I ^a   Sanz, J C ^a   Martinez M J ^b   Lopez Brea M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; BISMUTH CITRATE; EBROTIDINE; LANSOPRAZOLE; OMEPRAZOLE; RANITIDINE;

ANTIBACTERIAL ACTIVITY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DILUTION; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PRIORITY JOURNAL; STOMACH BIOPSY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BENZENESULFONATES; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TESTS; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; RANITIDINE; THIAZOLES;

EID: 0031822280     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050062     Document Type: Article

References (15)

1. Marshall BJ: Campylobacter pylori: its link to gastritis and peptic ulcer disease. Reviews of Infectious Diseases (1990) 12:587-593.
2. International Agency for Research on Cancer: Schistosomas, liver flukes and Helicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 61, WHO Publications, Geneva (1994) p. 270.
3. Labenz J, O'Morain C: Eradication. The year in Helicobacter pylori 1995. Current Opinion in Gastroenterology (1995) 11, Supplement 1:47-51.
4. Korman, MG: Helicobacter pylori eradication: therapy other than with bismuth or proton-pump inhibitors. Scandinavian Journal of Gastroenterology (1996) 220, Supplement: 41-43.
5. Lambert JR, Midolo P: The actions of bismuth in the treatment of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics (1997) 11, Supplement 1:27-33.
6. Wilde MI, McTavish D: Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs (1994) 48:91-132.
7. Dickey W, Kenny BD, McConnell JB: Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. Alimentary Pharmacology and Therapeutics (1996) 10:289-293.
8. Alarcón T, Domingo D, Sanchez I, Diaz de Rojas F, López-Brea M: In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:937-940.
9. Roine RP, Salmela KS, Hook-Nikanne J, Kosunen TU, Salaspuro M: Colloidal bismuth subcitrate and omeprazole inhibit alcohol dehydrogenase mediated acetaldehyde production by Helicobacter pylori. Life Sciences (1992) 51:195-200.
10. Patel SS, Wilde MI: Ebrotidine. Drugs (1996) 51:974-980.
11. Piotrowski J, Slomiany A, Slomiany BL: Inhibition of Helicobacter pylori urease activity by ebrotidine. Biochemistry and Molecular Biology International (1995) 37:247-253.
12. Piotrowski J, Piotrowski E, Slomiany A, Slomiany BL: Susceptibility of Helicobacter pylori to antimicrobial agents: effect of ebrotidine and ranitidine. Journal of Physiology and Pharmacology (1995) 46:463-469.
13. Mears JM, Kaplan B: Proton pump inhibitors: new drugs and indications. American Family Physician (1996) 53:285-292.
14. Figura N, Crabtree JE, Dattilo M: In vitro activity of lansoprazole against Helicobacter pylori. Journal of Antimicrobial Chemotherapy (1997) 39:585-590.
15. Nakao M, Tada M, Tsuchimori K, Uekata M: Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori. European Journal of Clinical Microbiology & Infectious Diseases (1995) 14:391-399.